Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Top Page
Shattuck Labs
(NASDAQ:STTK)
39Underperform
Positive Factors
Innovative Treatment Approach
The pivot into inflammatory bowel disease is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.
Investor Interest
Key Phase 1 milestones for SL-325 are expected to spur investor interest, marking the first clinical data following the company's strategic pivot.
Preclinical Data
Encouraging IND-enabling data for SL-325 indicates a clean safety profile and favorable dosing, which aligns with approved therapies.
Negative Factors
Enterprise Value
The opportunity for value inflection is seen given the company's negative enterprise value and the strategic pivot into a competitive IBD market.
Financial Performance
Shattuck posted a full-year EPS of ($1.49), which was below consensus estimates.
Pipeline Stage
Analyst maintains a Hold Rating given the early stage of the company pipeline at this time and a lack of near-term value drivers.
Shattuck Labs (STTK) vs. S&P 500 (SPY)
Market Cap
$45.51M
Dividend YieldN/A
Average Volume (3M)183.48K
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue Growth245.26%
EPS Growth27.54%
CountryUS
Employees44
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding47,899,240
10 Day Avg. Volume92,388
30 Day Avg. Volume183,479
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.90
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Shattuck Labs Business Overview & Revenue Model
Company DescriptionShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
How the Company Makes MoneyShattuck Labs generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve the co-development and commercialization of its proprietary ARC platform-based therapies. Additionally, the company may earn revenue from milestone payments and royalties associated with the successful advancement and commercialization of its therapeutic candidates. As a clinical-stage company, Shattuck Labs may also receive funding from grants or research collaborations to support its research and development activities.
Shattuck Labs Financial Statement Overview
Summary
Shattuck Labs shows strong revenue growth but remains unprofitable with significant operational challenges, including negative EBIT and EBITDA. The balance sheet is stable with low leverage, but ongoing losses and negative cash flows necessitate strategic adjustments.Income Statement
Shattuck Labs has shown significant revenue growth from the previous year, with a Revenue Growth Rate of approximately 245.32%. However, the company remains unprofitable with a negative Net Profit Margin of -131.82% and a negative EBIT Margin. The company has consistently generated negative EBIT and EBITDA over the years, indicating ongoing operational challenges.35
Negative
Balance Sheet
The balance sheet shows a stable equity position with a Debt-to-Equity Ratio of 0.03, indicating low leverage. The Equity Ratio of 87.47% suggests a strong equity base relative to total assets. However, the company has a history of net losses, which could impact future equity stability.55
Neutral
Cash Flow
Free cash flow remains negative, though there’s a slight improvement in free cash flow growth rate compared to previous years. The Operating Cash Flow to Net Income Ratio is negative, reflecting cash flow issues. The company's cash position has been supported by financing activities, highlighting reliance on external funding.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.72M | 1.66M | 652.00K | 30.02M | 9.93M | Gross Profit |
| 5.72M | -2.38M | -2.72M | 28.64M | -27.55M | EBIT |
| -80.57M | -91.96M | -103.33M | -45.27M | -36.93M | EBITDA |
| -80.57M | -87.61M | -100.26M | -43.89M | -36.31M | Net Income Common Stockholders |
| -75.41M | -87.30M | -100.56M | -44.35M | -35.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 57.39M | 130.63M | 161.28M | 268.80M | 335.45M | Total Assets |
| 91.05M | 159.56M | 205.32M | 298.58M | 348.99M | Total Debt |
| 2.51M | 4.20M | 4.20M | 0.00 | 0.00 | Net Debt |
| -54.88M | -121.42M | -43.18M | -92.27M | -157.90M | Total Liabilities |
| 11.42M | 14.86M | 29.17M | 26.80M | 39.13M | Stockholders Equity |
| 79.63M | 144.71M | 176.16M | 271.79M | 309.86M |
| Cash Flow | Free Cash Flow | |||
| -60.57M | -81.64M | -106.11M | -65.04M | -34.39M | Operating Cash Flow |
| -60.52M | -81.23M | -94.50M | -57.12M | -33.66M | Investing Cash Flow |
| -8.51M | 110.86M | 49.44M | -10.44M | -146.32M | Financing Cash Flow |
| 787.00K | 48.62M | 171.00K | 1.93M | 330.87M |
Shattuck Labs Technical Analysis
Negative
0.84
Price Trends
1.23
Negative
1.20
Negative
2.21
Negative
Market Momentum
-0.07
Positive
30.58
Neutral
3.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.23, and below the 200-day MA of 2.21, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 30.58 is Neutral, neither overbought nor oversold. The STOCH value of 3.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 55 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $50.93M | 1.48 | -58.97% | ― | 36.45% | ― | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $50.00M | 2.37 | 19.05% | ― | 40.98% | ― | |
43 Neutral | $50.30M | ― | -69.80% | ― | 56.62% | 26.48% | |
40 Underperform | $53.07M | ― | -204.95% | ― | -100.00% | 44.28% | |
39 Underperform | $45.51M | ― | -67.23% | ― | 245.26% | 27.54% | |
34 Underperform | $42.83M | ― | -79.26% | ― | ― | 14.06% |
* Healthcare Sector Average
Performance Comparison
STTK
Shattuck Labs
0.84
-7.94
-90.43%
CTMX
CytomX Therapeutics
0.61
-1.54
-71.63%
DTIL
Precision BioSciences
4.49
-10.95
-70.92%
KRON
Kronos Bio
0.81
-0.45
-35.71%
GANX
Gain Therapeutics
1.81
-2.18
-54.64%
PEPG
PepGen Inc.
1.46
-9.41
-86.57%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.